In vivo target validation by inducible RNAi in human xenograft mouse models

Marco Mazzoletti1, Gemma Texidó

  • 1Pharmacology Department of BU Oncology, Nerviano Medical Sciences, Nerviano, MI, Italy.

Insights

Target validation is key for developing new anti-cancer drugs. This study explores using genetically modified human xenograft mouse models to validate cancer targets in vivo, improving drug discovery.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Effective anti-cancer drug discovery relies on precise target selection and validation.
  • Tumor microenvironments are essential for cancer growth, necessitating in vivo validation of potential drug targets.

Purpose of the Study:

  • To describe the generation of genetically modified human xenograft mouse models.
  • To present an approach for validating oncology targets using these models.

Main Methods:

  • Generation of human xenograft mouse models.
  • Genetic modification of models to modulate cancer-related genes.
  • In vivo validation of oncology targets.

Main Results:

  • Successful generation of human xenograft mouse models with modulated cancer-related genes.
  • Demonstration of the utility of these models for in vivo target validation.

Conclusions:

  • Genetically modified human xenograft mouse models are a valuable tool for oncology target validation.
  • This approach enhances the reliability of anti-cancer agent discovery.